Hansa Biopharma (OTCPK:HNSB.F) - Prezzo delle azioni, notizie e analisi

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

HNSB.F Panoramica delle azioni

A biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Europe and the United States.

Informazioni sull'azienda

HNSB.F analisi fondamentale
Punteggio fiocco di neve
Valutazione	0/6
Crescita futura	2/6
Prestazioni passate	0/6
Salute finanziaria	2/6
Dividendi	0/6

Premi

Si prevede che i ricavi cresceranno 41.28% all'anno

Analisi del rischio

Patrimonio netto negativo

Le azioni sono altamente illiquide

Attualmente non redditizio e non si prevede che diventerà redditizio nei prossimi 3 anni

Gli azionisti sono stati diluiti nell'ultimo anno

Hansa Biopharma AB (publ) Concorrenti

GRAIL

NasdaqGS:GRAL

US$440.9m

Sutro Biopharma

NasdaqGM:STRO

US$304.1m

Voyager Therapeutics

NasdaqGS:VYGR

US$436.8m

Caribou Biosciences

NasdaqGS:CRBU

US$175.3m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Hansa Biopharma
Prezzi storici delle azioni
Prezzo attuale dell'azione	SEK 2.93
Massimo di 52 settimane	SEK 4.76
Minimo di 52 settimane	SEK 2.26
Beta	1.37
1Variazione di 1 mese	0%
Variazione a 3 mesi	n/a
Variazione di 1 anno	n/a
3Variazione a 3 anni	-82.13%
Variazione a 5 anni	-84.78%
Variazione dall'IPO	-36.30%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	HNSB.F	US Biotechs	US Mercato
7D	0%	0.6%	0.8%
1Y	n/a	27.4%	38.3%

Ritorno vs Industria: Dati insufficienti per determinare come si è comportato HNSB.F rispetto al settore US Biotechs.

Rendimento vs Mercato: Dati insufficienti per determinare la performance di HNSB.F rispetto al mercato US.

Volatilità dei prezzi

Is HNSB.F's price volatile compared to industry and market?
HNSB.F volatility
HNSB.F Average Weekly Movement	n/a
Biotechs Industry Average Movement	9.7%
Market Average Movement	6.2%
10% most volatile stocks in US Market	14.8%
10% least volatile stocks in US Market	3.0%

Prezzo delle azioni stabile: HNSB.F non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: Dati insufficienti per determinare la variazione della volatilità di HNSB.F nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2007	166	Søren Tulstrup	www.hansabiopharma.com

Hansa Biopharma AB (publ) Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Hansa Biopharma con la sua capitalizzazione di mercato?
HNSB.F statistiche fondamentali
Capitalizzazione di mercato	US$315.35m
Guadagni(TTM)	-US$80.44m
Ricavi(TTM)	US$15.79m

20.0x

Rapporto P/S

-3.9x

Rapporto P/E

HNSB.F è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
HNSB.F Conto economico (TTM)
Ricavi	SEK 165.88m
Costo del fatturato	SEK 71.66m
Profitto lordo	SEK 94.23m
Altre spese	SEK 939.10m
Guadagni	-SEK 844.88m

Ultimi guadagni dichiarati

Mar 31, 2024

Prossima data di guadagno

Jul 18, 2024

Utile per azione (EPS)	-13.38
Margine lordo	56.80%
Margine di profitto netto	-509.33%
Rapporto debito/patrimonio netto	-247.8%

Come si è comportato HNSB.F nel lungo periodo?

Vedi performance storica e confronto

HNSB.F Panoramica delle azioni

Premi

Analisi del rischio

Hansa Biopharma AB (publ) Concorrenti

NasdaqGS:GRAL

US$440.9m

NasdaqGM:STRO

US$304.1m

NasdaqGS:VYGR

US$436.8m

NasdaqGS:CRBU

US$175.3m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Hansa Biopharma's Hnsa-5487 Achieves Rapid and Highly Robust Igg Reduction by More Than 95% and Clear Redosing Potential in First-In-Human Trial

Hansa Biopharma AB (publ) to Report Nine Months, 2025 Results on Oct 23, 2025

Matthew Shaulis, Chief Commercial Officer and US President Decides to Leave Hansa Biopharma AB in Late September

Hansa Biopharma AB (publ) to Report Q1, 2025 Results on Apr 17, 2025

Hansa Biopharma AB (publ) Announces Board Appointments

Hansa Biopharma Completes Randomization in Pivotal Phase 3 Us Confides Trial

Recent updates

Hansa Biopharma's Hnsa-5487 Achieves Rapid and Highly Robust Igg Reduction by More Than 95% and Clear Redosing Potential in First-In-Human Trial

Hansa Biopharma AB (publ) to Report Nine Months, 2025 Results on Oct 23, 2025

Matthew Shaulis, Chief Commercial Officer and US President Decides to Leave Hansa Biopharma AB in Late September

Hansa Biopharma AB (publ) to Report Q1, 2025 Results on Apr 17, 2025

Hansa Biopharma AB (publ) Announces Board Appointments

Hansa Biopharma Completes Randomization in Pivotal Phase 3 Us Confides Trial

Hansa Biopharma AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 372.1536 million.

Hansa Biopharma AB (Publ) Announces CFO Changes

Hansa Biopharma AB (publ) to Report Nine Months, 2024 Results on Oct 24, 2024

Hansa Biopharma AB (publ), Annual General Meeting, Jun 27, 2024

Hansa Biopharma AB (Publ) Provides Earnings Guidance for the Fourth Quarter and Full Year 2023

Hansa Biopharma AB (Publ) Provides Earnings Guidance for the Fourth Quarter and Full Year 2023

Hansa Biopharma Announces Full Results from 16-HMedIdeS-12 Phase 2 Trial in Patients with Antibody Mediated Rejection Episodes Following Kidney Transplantation

Hansa Biopharma Nomination Committee Formed

Hansa Biopharma Announces Positive High-Level Data from the 15-HMedIdeS-09 Phase 2 Trial

Hahansa Biopharma AB (Publ) Announces Resignation of Donato Spota as Chief Financial Officer, Effective 28 February 2024

Hahansa Biopharma AB (Publ) Announces Resignation of Donato Spota as Chief Financial Officer, Effective 28 February 2024

Hahansa Biopharma AB (Publ) Announces Resignation of Donato Spota as Chief Financial Officer, Effective 28 February 2024

Hansa Biopharma Provides Update on ConfIdeS Phase 3 Trial of Imlifidase in Highly Sensitized Kidney Transplant Patients

Hansa Biopharma Announces Encouraging High-Level Results for First-In-Human Trial of HNSA-5487

Hitto Kaufmann Appointed Chief Scientific Officer of Hansa Biopharma, Effective 1 December 2023

Hitto Kaufmann Appointed Chief Scientific Officer of Hansa Biopharma

Hansa Biopharma AB (publ) to Report Q1, 2024 Results on Apr 17, 2024

Hansa Biopharma Announces First Patient Treated with Imlifidase in an Investigator-Initiated Phase 2 Study in Anca-Associated Vasculitis

Hansa Biopharma Receives Provisionally Approval in Australia as Desensitization Treatment in Highly Sensitized Patients Prior to Kidney Transplantation

Hansa Biopharma Announces First Patient Dosed with Imlifidase in a Global Pivotal Phase 3 Trial in Anti-Inaugular Basement Membrane (anti-GBM) Disease

Hansa Biopharma Announces Planned Departure of Chief Scientific Officer Christian Kjellman

Hansa Biopharma Announces Positive Reimbursement Decision for Idefirix[®] (Imlifidase) in the Czech Republic

Hansa Biopharma Announces Positive Reimbursement Decision for Idefirix[®] (Imlifidase) in the Czech Republic

Hansa Biopharma AB (publ) Announces Formation of Nomination Committee

Hansa Biopharma AB (publ) has completed a Follow-on Equity Offering.

Hansa Biopharma AB (Publ) Announces Positive Reimbursement Decision in Italy for Idefirix (Imlifidase) as Desensitization Treatment for Highly Sensitized Patients in Kidney Transplantation

Hansa Biopharma AB Announces Positive Topline Data from the Imlifidase Phase 2 Study in Antibody Mediated Rejection (AMR) Episodes Post Kidney Transplantation

Hansa Biopharma AB and Partner Sarepta Therapeutics Plan to Initiate A Clinical Study with Imlifidase as A Pre-Treatment to Sarepta's SRP-9001 Gene Therapy in DMD in 2023

Hansa Biopharma AB (publ) to Report First Half, 2023 Results on Jul 20, 2023

The Scottish Medicines Consortium Recommends Use of Hansa Biopharma's Idefirix[®] (Imlifidase) as Desensitization Treatment for Highly Sensitized Kidney Transplant Patients

Hansa Biopharma AB and Medison Pharma Announce Positive Reimbursement Decision in Poland for Idefirix in Highly Sensitized Kidney Transplant Patients

Hansa Biopharma AB (publ) announced that it has received $70 million in funding from NovaQuest Capital Management, L.L.C.

Hansa Biopharma Announces First Patient Treated in the Post-Authorization Efficacy Study (PAES) of Idefirix® (Imlifidase) in Highly Sensitized Kidney Transplant Patients

Hansa Biopharma AB (publ) Appoints Peter Nicklin as A New Member of the Board of Director

NICE Recommends Use of Hansa Biopharma's Idefirix (Imlifidase) as Desensitization Treatment for Highly Sensitized Kidney Transplant Patients

Hansa Biopharma AB (publ) Announces Ulf Wiinberg Not to Stand for Re-Election as Director

Hansa Biopharma Completes Enrollment in Imlifidase Phase 2 Study in Antibody Mediated Rejection (AMR) Episodes Post Kidney Transplantation

Hansa Biopharma Announces Temporary Marketing Authorization in Switzerland for Idefirix (Imlifidase) in Kidney Transplantation

Hansa Biopharma Announces U.S. Fda Acceptance of Investigational New Drug (Ind) Application for Phase 3 Study of Imlifidase in Anti-Gbm Disease

Hansa Biopharma AB and Medison Pharma Announces Marketing Authorization in Israel for Idefirix for Desensitization Treatment of Highly Sensitized Kidney Transplant Patients

Hansa Biopharma AB Announces Grant of Early Access Post Marketing Authorization for its First-In-Class Treatment Idefirix® (imlifidase)

Hansa Biopharma AB Announces Positive Early Access Decision by French Haute Autorité De Santé to Use Idefirix® (Imlifidase) as Desensitization Treatment for Highly Sensitized Kidney Transplant Patients

Hansa Biopharma Enrolls First Patient in U.S. Randomized, Controlled Pivotal Trial of imlifidase in Highly Sensitized Kidney Transplant Patients

Rendimenti per gli azionisti

Volatilità dei prezzi

Informazioni sull'azienda

Hansa Biopharma AB (publ) Riepilogo dei fondamenti

20.0x

-3.9x

Guadagni e ricavi